EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Peripheral metabolic–redox signaling as a core mechanism of major depressive disorder: evidence from deep metabolomic phenotyping

Michael Maes iD, Mengqi Niu, Annabel Maes, Yiping Luo, Chenkai Yangyang, Abbas F Almulla iD, Jing Li, Yingqian Zhang

Acta Neuropsychiatrica · 2026 · 38

DOI: 10.1017/neu.2026.10065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropsychiatrica, online erschienen am 24.02.2026. Verfasst von Michael Maes und 7 weiteren Autor:innen. Beteiligte Einrichtung: International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of El…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Metabolomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Major depressive disorder (MDD) is a neuro-immune, oxidative, and nitrosative stress (NIMETOX) disorder, in which peripheral immune-redox pathways intersect with metabolic networks leading to neurotoxicity within the limbic-prefrontal affective circuits. Comprehensive metabolomics analysis in well-phenotyped patients is vital to elucidate their metabolic profile.

Objectives

To identify metabolic abnormalities that differentiate in patients with severe MDD from healthy controls(HCs) through high-resolution, untargeted metabolomics.

Methods

Serum samples from 125 MDD inpatients and 40 HCs were analyzed utilizing liquid chromatography(LC) and mass spectrometry(MS). A meticulously regulated multistage machine-learning pipeline with leakage-prevention protocols was employed to analyze differences between MDD and controls and to predict phenome scores.

Results

Feature selection showed that 16 metabolites and 6 functional modules reliably distinguished MDD. The functional profile of the metabolites indicates a convergence of lipotoxicity, phospholipid(PL) remodeling, disruptions in fatty acid(FA) metabolism, mitochondrial redox imbalance, ether-lipid metabolism, and antioxidant depletion. This MDD metabotype was not affected by metabolic syndrome(MetS). A substantial portion of the variance in overall depression severity (72.5%), physiosomatic symptoms (55.8%), and suicidal ideation(SI) (23.6%) was accounted for by increased lipotoxicity, PL remodeling, and FA storage/signaling. The recurrence of illness (27.7%) was associated with a self-reinforcing lipid-redox-inflammatory module that maintains cellular stress.

Discussion

The MDD metabotype represents a cohesive metabolic network that is associated with the NIMETOX pathogenesis of MDD. Metabolomics provides a comprehensive foundation for subtyping and precision psychiatry. Lipoxygenase-15, lipotoxicity, phospholipase A 2 , and lipid-redox intersections might be important drug targets to treat MDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderMetabolomicsHumansOxidation-ReductionFemaleAdultMaleSignal TransductionMiddle AgedPhenotypeOxidative StressLipid MetabolismMetabolome

Stichwörter der Autor:innen

antioxidantslipidsmetabolismneuro-immunenomothetic precision psychiatryoxidative and nitrosative stress

Autor:innen und Institutionen

  • International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, China.
  • Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, China.
  • Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.
  • Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria.
  • Research and Innovation Program for the Development of MU - PLOVDIV (SRIPD-MUP), Creation of a network of research higher schools, National Plan for Recovery and Sustainability, European Union - NextGenerationEU, Medica…

ORCID-Profile: Michael Maes, Abbas F Almulla

Zitieren

APA

Maes, M., Niu, M., Maes, A., Luo, Y., Yangyang, C., Almulla, A. F., Li, J., & Zhang, Y. (2026). Peripheral metabolic–redox signaling as a core mechanism of major depressive disorder: evidence from deep metabolomic phenotyping. Acta Neuropsychiatrica, 38. https://doi.org/10.1017/neu.2026.10065

Vancouver

Maes M, Niu M, Maes A, Luo Y, Yangyang C, Almulla AF, et al. Peripheral metabolic–redox signaling as a core mechanism of major depressive disorder: evidence from deep metabolomic phenotyping. Acta Neuropsychiatrica. 2026;38. doi:10.1017/neu.2026.10065

BibTeX
@article{Maes2026,
  author = {Maes, Michael and Niu, Mengqi and Maes, Annabel and Luo, Yiping and Yangyang, Chenkai and Almulla, Abbas F and Li, Jing and Zhang, Yingqian},
  title = {Peripheral metabolic–redox signaling as a core mechanism of major depressive disorder: evidence from deep metabolomic phenotyping},
  journal = {Acta Neuropsychiatrica},
  year = {2026},
  volume = {38},
  doi = {10.1017/neu.2026.10065}
}
Kostenlos starten →